Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) saw strong trading volume on Friday . 2,978,328 shares traded hands during trading, an increase of 1,608% from the previous session’s volume of 174,420 shares.The stock last traded at $1.65 and had previously closed at $1.19.

Several research analysts recently issued reports on the stock. ValuEngine cut shares of Eleven Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, June 13th. Zacks Investment Research raised shares of Eleven Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th.

The stock has a 50-day moving average of $1.29 and a 200-day moving average of $1.63. The stock has a market capitalization of $25.40 million, a PE ratio of 15.14 and a beta of 3.37.

Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings data on Monday, August 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter. Eleven Biotherapeutics had a net margin of 11.28% and a return on equity of 4.26%. Equities analysts predict that Eleven Biotherapeutics, Inc. will post ($1.75) EPS for the current fiscal year.

A number of large investors have recently modified their holdings of EBIO. Virtu KCG Holdings LLC bought a new stake in Eleven Biotherapeutics in the 2nd quarter valued at about $175,000. Spark Investment Management LLC bought a new stake in Eleven Biotherapeutics in the 2nd quarter valued at about $148,000. Finally, Vanguard Group Inc. lifted its position in Eleven Biotherapeutics by 17.4% in the 2nd quarter. Vanguard Group Inc. now owns 206,450 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 30,600 shares during the last quarter. Hedge funds and other institutional investors own 5.05% of the company’s stock.

WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.dailypolitical.com/2017/09/08/eleven-biotherapeutics-inc-ebio-sees-large-volume-increase-4.html.

Eleven Biotherapeutics Company Profile

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.